Cargando…
Azithromycin for mild-to-moderate COVID-19 – Authors' reply
Autor principal: | Hinks, Timothy S C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428487/ https://www.ncbi.nlm.nih.gov/pubmed/34509195 http://dx.doi.org/10.1016/S2213-2600(21)00376-3 |
Ejemplares similares
-
Azithromycin for mild-to-moderate COVID-19
por: Patel, Jigar, et al.
Publicado: (2021) -
Cancer and COVID-19 – Authors' reply
por: Kuderer, Nicole M, et al.
Publicado: (2020) -
Remdesivir and COVID-19 – Authors' reply
por: Wang, Yeming, et al.
Publicado: (2020) -
Reply to Alizazgar J. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients
por: Honoré, Stéphane, et al.
Publicado: (2021) -
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
por: Cavalcanti, Alexandre B., et al.
Publicado: (2020)